Literature DB >> 12894494

Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning.

Ole K Olstad1, Vigdis T Gautvik, Sjur Reppe, Edith Rian, Rune Jemtland, Claes Ohlsson, Oyvind S Bruland, Kaare M Gautvik.   

Abstract

Directional tag PCR subtractive hybridization was applied to construct a cDNA library generated from three different human osteosarcoma (OS) target cell lines (OHS, SaOS-2 and KPDXM) from which normal osteoblast (NO) sequences were subtracted. After two consecutive subtractive steps more than 98% of the common mRNAs species were depleted, leading to effective enrichment of the remaining target sequences. After differential screening of 960 clones, 81 candidates were further studied by Northern blot analysis and 73 represented separate mRNA species. Fifty-three of these showed enriched mRNA levels, of which 36 represented known and 17 not previously published cDNAs or EST sequences. The mRNAs showed a 1.4- to 504-fold enrichment compared to the mRNA levels in NO cells. The known mRNAs are: Ribosomal protein S11, KSP-37, Tethering factor SEC34, FXYD6, Alpha enolase, G-s-alpha, GPR85, DAF, RPL35A, GIF, TAPA-1, ANAPC11, DCI, hsp27, MRPS7 homolog, eIF p110 subunit, DPH2L, HMG-14, FB1 protein, chondroitin-6-sulphonase, calgizzarin, RNA polymerase II subunit, RPL13A, DHS, gp96, HHP2, acidic ribosomal phosphoprotein P2, ANT-2, ARF1, AFG3L2, SKD3, phosphoglucoisomerase, GST pi, CKI gamma 2, DNA polymerase delta small subunit and TRAP delta. Sections of human osteosarcoma biopsies and a xenograft were studied by in situ analysis. Seven cDNAs highly expressed in Northern blot analysis were tested. Their in situ expression differed between the xenograft and human sections as did that of collagen I. In the xenograft made from one of the target cell lines (OHS), a fair to strong representation of 3 cloned mRNAs was observed while collagen I mRNA was not detectable. We conclude that the molecular heterogeneity of these tumors is considerable. These results ought to have implications for future work to describe phenotypic subtypes with the aim of improving the diagnosis of human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894494

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Stem-like cells in bone sarcomas: implications for tumorigenesis.

Authors:  C Parker Gibbs; Valery G Kukekov; John D Reith; Olga Tchigrinova; Oleg N Suslov; Edward W Scott; Steven C Ghivizzani; Tatyana N Ignatova; Dennis A Steindler
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

2.  POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.

Authors:  Bente Vilming Elgaaen; Kari Bente Foss Haug; Junbai Wang; Ole Kristoffer Olstad; Dario Fortunati; Mathias Onsrud; Anne Cathrine Staff; Torill Sauer; Kaare M Gautvik
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

3.  Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity.

Authors:  Ling Yu; Shiqing Liu; Chun Zhang; Bo Zhang; Bruno M Simões; Rachel Eyre; Yi Liang; Huichao Yan; Zheng Wu; Weichun Guo; Robert B Clarke
Journal:  Oncotarget       Date:  2013-12

4.  FXYD6 is a new biomarker of cholangiocarcinoma.

Authors:  Xiongfei Chen; Mingzhu Sun; Yazhuo Hu; Honghong Zhang; Zhanbo Wang; Ningxin Zhou; Xinyun Yan
Journal:  Oncol Lett       Date:  2013-12-04       Impact factor: 2.967

5.  Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data.

Authors:  Zuozhang Yang; Yongbin Chen; Yu Fu; Yihao Yang; Ya Zhang; Yanjin Chen; Dongqi Li
Journal:  BMC Med Genet       Date:  2014-07-14       Impact factor: 2.103

6.  Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma.

Authors:  Gaia Palmini; Roberto Zonefrati; Carmelo Mavilia; Alessandra Aldinucci; Ettore Luzi; Francesca Marini; Alessandro Franchi; Rodolfo Capanna; Annalisa Tanini; Maria Luisa Brandi
Journal:  J Vis Exp       Date:  2016-10-14       Impact factor: 1.355

Review 7.  Arf proteins in cancer cell migration.

Authors:  Cristina Casalou; Alexandra Faustino; Duarte C Barral
Journal:  Small GTPases       Date:  2016-09-02

Review 8.  The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective.

Authors:  Cristina Casalou; Andreia Ferreira; Duarte C Barral
Journal:  Front Cell Dev Biol       Date:  2020-04-21

9.  Screening of disorders associated with osteosarcoma by integrated network analysis.

Authors:  Yongfeng Dou; Kai Zhu; Zhaozhong Sun; Xiaopeng Geng; Qingmin Fang
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.